Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. Jul/Aug 2018;24(4):187-192.
doi: 10.1097/PPO.0000000000000324.

Bevacizumab in Cervical Cancer: 5 Years After

Affiliations
Review

Bevacizumab in Cervical Cancer: 5 Years After

Krista S Pfaendler et al. Cancer J. .

Abstract

Over the past 5 years, addition of bevacizumab to combination chemotherapy for advanced, recurrent, and persistent cervical cancer has offered prolonged overall and progression-free survival. Since the original press release announcing the survival benefits of this antiangiogenesis therapy, there has been further study of bevacizumab related to quality of life, combination with other agents, use of imaging to evaluate likelihood of response, and development of biosimilars. This review summarizes publications related to bevacizumab use in advanced, recurrent, and persistent cervical cancer over the past 5 years since initial proof of concept of antiangiogenesis therapy and the initial dissemination of information regarding survival benefits of bevacizumab.

Similar articles

See all similar articles

Cited by 2 articles

MeSH terms

Substances

Feedback